Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RD13-02 CAR-T in CD7-positive Hematologic Malignancies
NCT05907603Phase 1Completed
- Start
- Mar 2023
- Primary completion
- Aug 2024
- Modality
- CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label trial of RD13-02 in acute lymphoblastic leukemia (ALL), lymphoblastic lymphoma (LBL) and acute myeloid leukemia (AML). Primary endpoint: Overall Response Rate at 4 weeks. Started Mar 2023; status: completed.
02
Drugs
RD13-02
03
Conditions
acute lymphoblastic leukemia (ALL)lymphoblastic lymphoma (LBL)acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT05907603.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05907603.